Pharma Pulse 8/2/24: Poor Data is a Population Health Risk, Meta’s Earnings Calm AI Jitters & more

Current Uses of LLMs in Clinical Trials

In part 1 of this video interview, Rama Kondru, PhD, CEO of Veridix AI discusses challenges with adoption and the potential uses of large language models in clinical trials.

Poor Data is a Population Health Risk. Ready Access to Quality Data Can Help

Intermountain Health leveraged a self-service data platform that used algorithms to identify chronic kidney disease patients and stratify them based on gaps in care.

Meta’s earnings calm A.I. jitters

Another tech giant has run the gantlet of investor worries about the costs of commercializing artificial intelligence — except that this one passed with flying colors.

Mental Health Leaves of Absence Continue to Proliferate Among U.S. Workers According to New ComPsych Data

ComPsych® Corporation has released new data that shows mental health related leaves continue to skyrocket among U.S. workers. A sample analysis of ComPsych’s absence book of business, which covers more than six million people, found that in the first quarter of 2024, more than one in ten (11%) of all leaves of absence were due to mental health. This represents a 22% increase in mental health leaves versus those taken in the first quarter of 2023. This trend is being driven by female workers, who accounted for 69% of all mental health leaves of absence in 2023, and 71% of all mental health leaves in the first quarter of 2024.

Femasys Inc. on LinkedIn

Thank you, @Don Tracy of Pharmaceutical Executive for bringing awareness to the ongoing legal battles over women's health issues. In their latest article, our CEO Kathy Lee-Sepsick discussed the importance of women’s health access and the need for more reproductive care options. Highlighted are our groundbreaking advancements:

FemaSeed: FDA-cleared last September, FemaSeed offers a less invasive, more affordable infertility treatment compared to IVF. It enhances natural conception by placing sperm directly into the fallopian tube.

FemBloc: Our permanent birth control solution, currently being studied in clinical trial, provides a non-surgical alternative to tubal ligation.

Kathy's positive outlook on the future of women’s reproductive rights reflects our commitment at Femasys to advancing women's health technologies despite regulatory and funding challenges.

Read the full article for more insights: https://lnkd.in/gXSQStg4

#Femasys #WomensHealth #FemaSeed #FemBloc #ReproductiveRights

Have news you want us to share in Pharma Pulse? Reach out to Social Media Editor Miranda Schmalfuhs